NeuroMetrix, Inc. (NURO) Initiates Patient-Focused Program For Early Detection Of Diabetic Peripheral Neuropathy By Podiatrists
4/1/2014 1:59:35 PM
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that helps patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today announced an initiative to improve the detection and awareness of diabetic peripheral neuropathy, or DPN, at a reasonable cost to patients. The program is targeted at podiatric physicians and offers creative commercial terms to incorporate a DPN screening program into their clinical practice with NC-stat® DPNCheck® technology. This objective test will allow them to more accurately assess their patients with diabetes for DPN and enhance the podiatric care they provide.
Help employers find you! Check out all the jobs and post your resume.
comments powered by